Elevated blood levels of IL-6 and IL-10 in ER + BC suggest a pro-inflammatory environment that can chronically activate pathways such as IL-6/STAT3, which are known to correlate with poorer survival outcomes and may reflect more aggressive disease states [1,2,35]. This evidence concerns the gene IL6 and breast cancer.